THE 30-SECOND OVERVIEW
At a glance
Sermorelin and ipamorelin are the two growth hormone secretagogues most often set against each other, usually as though the choice were between two versions of the same thing. They are not. One is a fragment of human growth hormone-releasing hormone acting at the GHRH receptor. The other is a synthetic pentapeptide acting at the ghrelin receptor. Their only shared property is that both raise growth hormone, and they do it through machinery that does not overlap.
Two separate receptor systems
Sermorelin is GHRH(1-29), the shortest fragment of endogenous human GHRH that retains full activity at the GHRH receptor. Native GHRH is 44 amino acids; the first 29 carry the receptor binding, and everything past that is dispensable for potency.
Ipamorelin has no structural relationship to GHRH at all. It is a synthetic pentapeptide that binds GHS-R1a, the ghrelin receptor, and it belongs to the growth hormone-releasing peptide family alongside GHRP-2 and GHRP-6. The other route into GHS-R1a is not a peptide: MK-677 liquid, the orally active small-molecule ghrelin mimetic, reaches the same receptor by mouth.
Somatotrophs in the anterior pituitary carry both receptors. Stimulating either raises growth hormone. Stimulating both produces more release than either alone in preclinical work, which is the entire mechanistic argument behind combination protocols, and it holds only because the two receptors are genuinely independent rather than two routes into the same switch.
Ipamorelin was built for selectivity
The GHRP family has a known problem. GHRP-6 and GHRP-2 raise growth hormone effectively, but at working quantities they also raise cortisol and prolactin, because the ghrelin receptor sits in signalling territory that touches the HPA axis.
Ipamorelin was developed specifically to separate those effects. Its original characterisation reported growth hormone release comparable to GHRP-6 without the accompanying cortisol and prolactin elevation across the studied range. That selectivity is the reason it displaced the older GHRPs in research protocols, and it is the single most defensible claim in its literature.
Sermorelin has no equivalent issue to solve. GHRH receptor stimulation does not carry the same off-target signalling, so selectivity was never the design problem for a GHRH fragment.
Neither has a modern trial record
This is where both compounds sit in a weaker position than the discussion around them suggests.
Sermorelin held FDA approval as Geref for growth hormone deficiency in children, and it was used diagnostically to test pituitary responsiveness. It was withdrawn from the US market in 2008. The withdrawal followed commercial decisions and the availability of recombinant growth hormone rather than any safety finding, a distinction that secondary sources frequently get backwards. What remains is an approval for a different indication, in a different population, under evidentiary standards from decades ago.
Ipamorelin never had an approval at all. It was characterised in animal models in the late 1990s, entered clinical development for postoperative ileus, and that programme was discontinued. There is no phase 3 dataset and no long-term human safety record.
So the honest comparison is not between a well-evidenced compound and a poorly-evidenced one. It is between two compounds whose human data is thin in different ways: one has old data for an unrelated indication, the other has almost none.
Half-life explains the protocol differences
Sermorelin is an unprotected GHRH fragment, and dipeptidyl peptidase-4 cleaves it near the N-terminus within minutes. Its reported circulating half-life is roughly 10 to 20 minutes, which produces a sharp, brief growth hormone pulse. That profile is precisely what made it useful as a diagnostic agent, where a clean provocative response is the point.
Ipamorelin's half-life is longer, reported in the region of two hours, though still short enough that research protocols involving it tend toward frequent administration.
Neither compound sustains elevation the way an albumin-bound or enzymatically protected analogue does. Both produce pulses. That matters because growth hormone is normally secreted in pulses, and the pattern is thought to carry signalling information rather than being incidental to it.
Both depend on a working pituitary
Neither compound supplies growth hormone. Both provoke its release, which means both require somatotrophs capable of responding and both remain subject to somatostatin's inhibitory feedback.
That shared dependency is the reason secretagogues are studied as an alternative to administering growth hormone directly: the resulting release stays inside normal regulatory control. It is also the shared ceiling. Where pituitary capacity is the limiting factor, neither compound addresses it, and no combination of the two changes that.
What the combination research actually shows
Ipamorelin appears constantly in stacking discussion, most often paired with a GHRH analogue. The mechanistic rationale is real and rests on the receptor independence described above.
What does not exist is a substantial body of clinical work evaluating any of these combinations in humans. The additive release is a preclinical finding. Protocols built on it are extrapolations from receptor pharmacology, not studied regimens, and they should be described that way rather than presented as established practice.
What neither compound's data establishes
Growth hormone and IGF-1 elevation are measured biochemical outcomes. They are not the same as any downstream result, and the gap between the two is not small. Neither sermorelin nor ipamorelin has published human work measuring body composition, recovery, or any other endpoint against placebo at a scale that would settle the question.
Neither holds current approval anywhere. Both are supplied for research use only.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
2. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157.
3. Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316-1329.
4. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412-1416.
